PEGylated recombinant human soluble tumour necrosis factor receptor type I (r-Hu-sTNF-RI): Novel high affinity TNF receptor designed for chronic inflammatory diseases

Annals of the Rheumatic Diseases

Volumn 58, Issue SUPPL. 1, 1999, Pages

  Edwards III, Carl K ^a  

^a AMGEN INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ESCHERICHIA COLI LIPOPOLYSACCHARIDE; MACROGOL; STAPHYLOCOCCUS ENTEROTOXIN B; TUMOR NECROSIS FACTOR RECEPTOR;

ANIMAL MODEL; BABOON; CHIMPANZEE; CHRONIC INFLAMMATION; CROHN DISEASE; DOSE RESPONSE; DRUG EFFECT; DRUG RESPONSE; DRUG SCREENING; MONKEY; MOUSE; NONHUMAN; PRIORITY JOURNAL; RAT; REVIEW; RHEUMATOID ARTHRITIS;

ANIMALS; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; DISEASE MODELS, ANIMAL; DRUG DESIGN; HUMANS; RECEPTORS, TUMOR NECROSIS FACTOR; RECEPTORS, TUMOR NECROSIS FACTOR, TYPE I; TUMOR NECROSIS FACTOR DECOY RECEPTORS; TUMOR NECROSIS FACTOR-ALPHA;

EID: 0032725837     PISSN: 00034967     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (74)

1. Carswell EA, Old LJ, Kassel RL, Green S, Fiore N, Williamson B. An endotoxin-induced serum factor that causes necrosis of tumors. Proc Natl Acad Sci USA 1975;72:847.
2. Tracey KJ. TNF and Mae West or: death from too much of a good thing. Lancet [commentary]. 1995;345:75-6.
3. Bazzoni F, Beutler B. The tumor necrosis factor ligand and receptor families. N Engl J Med 1996;334:1717-25.
4. Brennan FM, Maini RN, Feldmann M. Role of pro-inflammatory cytokines in rheumatoid arthritis. Springer Semin Immunopathol 1998;20:133-47.
5. Firestein GS, Zvaifler N. Anticytokine therapy in rheumatoid arthritis. N Engl J Med 1997;337:195-7.
6. Beutler B, Cerami A. The biology of cachectin/TNF - a primary mediator of the host response. Annu Rev Immunol 1989;7:625-55.
7. Edwards III CK, Borcherding S, Zhang J, Borcherding DR, Laskin DL. Role of tumor necrosis factor-alpha (TNF-alpha) in acute and chronic inflammatory responses: novel therapeutic approaches. In: Schook LB, ed. Xenobiotic induced inflammation: roles of cytokines and growth factors. New York, NY: Academic Press, 1994:97-147.
8. Evans TJ, Moyes D, Carpenter A, et al. Protective effect of 55-Kd but not 75-Kd soluble tumor-necrosis-factor receptor immunoglobulin-G fusion proteins in an animal-model of Gram-negative sepsis. J Exp Med 1994;180:2173-9.
9. Fisher Jr CJ, Agosti JM, Opal SM, et al. Treatment of septic shock with the tumor necrosis factor receptor: Fc fusion protein. N Engl J Med 1996;334:1697-702.
10. Beutler BA. The role of tumor necrosis factor in health and disease. J Rheumatol 1999;26:16-21.
11. Feldmann M, Brennan F, Paleolog E, Taylor P, Maini RN. Anti-tumor necrosis factor alpha therapy of rheumatoid arthritis. Eur Cytokine Netw 1997;8:297-300.
12. Beutler B, Van Huffel C. Unraveling function in the TNF ligand and receptor families. Science 1994;264:667-709.
13. Banner DW, D'Arcy A, Janes W, et al. Crystal structure of the soluble human 55 kd TNF receptor-human TNF beta complex: implications for TNF receptor activation. Cell 1993;73:431-45.
14. Suda T, Takahashi T, Golstein P, Nagata S. Molecular cloning and expression of the Fas ligand, a novel member of the tumor necrosis factor family. Cell 1993;75:1169-78.
15. Grell M, Wajant H, Zimmerman G, Scheurich P. The type 1 receptor (CD120a) is the high-affinity receptor for soluble tumor necrosis factor. Proc Natl Acad Sci USA 1998,95: 570-5.
16. Watts AD, Hunt NH, Wanigasekara Y, et al. A casein kinase I motif present in the cytoplasmic domain of members of the tumour necrosis factor ligand family is implicated in 'reverse signalling'. EMBO J 1999;18:2119-26.
17. Cope AP, Maini RN. Soluble tumor necrosis factor receptors in arthritis. J. Rheumatol. 1995;22:382-4.
18. Kohno T, Brewer MT, Baker SL, et al. A second tumor necrosis factor gene product can yield a naturally occuring tumor necrosis factor inhibitor. Proc Natl Acad Sci USA 1990;87:8331-5.
19. Van Zee KJ, Kohno T, Fischer E, Rock CS, Moldawer LL, Lowry SF. Tumor necrosis factor soluble receptors circulate during experimental and clinical inflammation and can protect against excessive tumor necrosis factor alpha in vitro and in vivo. Proc Natl Acad Sci USA 1992;89:4845-9.
20. Bendele A, McComb J, Gould T, et al. Animal models of arthritis: relevance to human disease. Toxicol Pathol 1999; 27:134-42.
21. Bendele AM, McComb J, Gould T, et al. Combination benefit of PEGylated soluble tumor necrosis factor receptor type I (PEG sTNF-RI) and dexamethasone or indomethacin in adjuvant arthritic rats. Inflamm Res 1999;48:453-60.
22. Bendele AM, McComb J, Gould T, et al. Effects of PEGylated soluble tumor necrosis factor receptor type I (PEG sTNF-RI) alone ands in combination with methotrexate in adjuvant arthritic rats. Clin Exp Rheumatol (in press).
23. McComb J, Gould T, Chlipala E, et al. Anti-arthritic activity of soluble TNF receptor forms in adjuvant arthritis: correlation of plasma levels with efficacy. J Rheumatol 1999;26:1347-51.
24. Elliott MJ, Maini RN, Feldmann M, et al. Randomised double-blind comparison of chimeric monoclonal antibody to tumour necrosis factor alpha (cA2) versus placebo in rheumatoid arthritis. Lancet 1994;344:1105-10.
25. Elliott MJ, Maini RN, Feldmann M, et al. Treatment of rheumatoid arthritis with chimeric monoclonal antibodies to tumor necrosis factor alpha. Arthritis Rheum 1993;36: 1681-90.
26. Elliott MJ, Maini RN, Feldmann M, et al. Repeated therapy with monoclonal-antibody to tumor necrosis factor alpha (cA2) in patients with rheumatoid arthritis. Lancet 1994;344:1125-7.
27. Solorzano C, Kaibara A, Hess PJ, et al. Pharmacokinetics, immunogenicity and efficacy of dimeric TNFR binding proteins in healthy and bacteremic baboon. J Appl Physiol 1998;84:1119-30.
28. Yang SP, Edwards III CK, Mountz JD. Soluble TNF receptor prevents arthritis and pneumonitis in motheaten mice. Arthritis Rheum 1998;41:139-49.
29. Russell D, Tucker H, Kohno H, Thompson RC. Inhibition of tumor necrosis factor (TNF) is effective alone or in combination with inhibition of interleukin-1 (IL-1) in reducing joint swelling in rodent bacterial cell wall-induced arthritis. Arthritis Rheum 1996;37:s279.
30. Espat NJ, Cendan JC, Beierle EA, et al. PEG-BP-30 mono-therapy attenuates the cytokine-mediated inflammatory cascade in baboon Escherichia coli septic shuck. J Surg Res 1995;59:153-8.
31. Solorzano CC, Ksontini R, Pruitt JH, et al. Involvement of 26-kDa cell associated TNFμ in experimental hepatitis and exacerbation of liver injury with a matrix metalloproteinase inhibitor. J Immunol 1997;158:414-19.
32. Milani RV, Mehra MR, Endres S, et al. The clinical relevance of circulating tumor necrosis factor-alpha in acute decompensated chronic heart failure without cachexia. Chest 1996;110:992-5.
33. Marriott JB, Westby M, Dalgleish A. Therapeutic potential of TNF-α inhibitors old and new. Drug Development Today 1997;2:273-81.
34. Van Zee KJ, Moldawer LL, Oldenburg HS, et al. Protection against lethal Escherichia bacteremia in baboons (Papio anubis) by pretreatment with a 55-kDa TNF receptor (CD120a)-Ig fusion protein, Ro 45-2081. J Immunol 1996;156:2221-30.
35. Fisher CJ Jr, Agosti JM, Opul SM, Lowry SF, Balk RA, Sadoff JC. Treatment of septic shock with the tumor necrosis factor receptor:Fc. N Engl J Med 1996,334:1697-702.
36. Abraham E, Glauser MP, Butler T, et al. p55 tumor necrosis factor receptor fusion protein in the treatment of patients with severe sepsis and septic shock. A randomized controlled multicenter trial. JAMA 1997;277:1531-8.
37. Moreland LW. Inhibitors of tumor necrosis factor for rheumatoid arthritis. J Rheumatol 1999;26:7-15.
38. Aderka D, Engelmann H, Maor Y, Brakebusch C, Wallach D. Stabilization of the bioactivity of tumor necrosis factor by its soluble receptors. J Exp Med 1992;175:323-9.
39. Mohler KM, Torrance DS, Smith CA, et al. Soluble tumor necrosis factor (TNF) receptors are effective therapeutic agents in lethal endotoxemia and function simultaneously as both TNF carriers and TNF antagonists. J Immunol 1993;151:1548-61.
40. Tartaglia IA, Pennica D, Goeddel DV. Ligand passing: the 75-Kd tumor necrosis factor (TNF) receptor recrutis TNF for signaling by the 55 Kd TNF receptor. J Biol Chem 1993;268:18542-8.
41. Ksontini R, MacKay SL, Moldawer LL. Revisiting the role of tumor necrosis factor alpha and the response to surgical injury and inflammation. Arch Surg 1999;133:558-67.
42. Grau G E, Maennel DN. TNF inhibition and sepsis-sounding a cautionary note. Nat Med 1997;3:1193-5.
43. Lorenz HM, Kalden JR. Biologic agents in the treatment of inflammatory rheumatic diseases. Curr Opin Rheumatol 1999;11:179-84.
44. Dayer J, Burger D, Interleukin-I, tumor necrosis factor and their specific inhibitors. European Cytokine Review 1994;5:563-71.
45. Arend WP, Dayer JM. Cytokines and cytokine inhibitors or antagonists in rheumatoid arthritis. Arthritis Rheum 1990; 33:305-15.
46. Arend WP, Dayer JM. Inhibition of the production and effects of interleukin-1 and tumor necrosis factor alpha in rheumatoid arthritis. Arthritis Rheum 1995;38:151-60.
47. Cope AP. Regulation of autoimmunity by proinflammatory cytokines. Curr Opin Immunol 1998;10:669-76.
48. Feldmann M, Brennan FM, Chantry D, et al. Cytokine production in the rheumatoid joint: implications for treatment. Ann Rheum Dis 1990;49:480-6.
49. Butler DM, Malfait A, Mason LJ, et al. DBA/1 mice expressing the human TNF-alpha transgene develop a severe, erosive arthritis. J Immunol 1997;159:2876.
50. Alsalameh S, Winter K, Al-Ward R, Wendler J, Kalden JR, Kinne RW. Distribution of TNF-alpha, TNF-R55 and TNF-R75 in the rheumatoid synovial membrane: TNF receptors are localized preferentially in the lining layer; TNF-alpha is distributed mainly in the vicinity of TNF receptors in the deeper layers. Scand J Immunol 1999;49: 278-85.
51. Hale KK, Smith CG, Baker SL, et al. Multifunctional regulation of the biological effects of TNF-alpha by the soluble type I and type II TNF receptors. Cytokine 1995;7:26-38.
52. Desgeorges A, Gabay C, Silacci P, et al. Concentration and origins of soluble interleukin 6 receptor-alpha in serum and synovial fluid. J Rheumatol 1997;24:1510-16.
53. Brennan FM, Gibbons DL, Cope AP, Katsikis P, Maini RN, Feldmann M. TNF inhibitors are produced spontaneously by rheumatoid and osteoarthritic synovial joint cell cultures: evidence of feedback control of TNF action. Scand J Immunol 1995;42:158-65.
54. Felson DT, Anderson JJ, Boers M, et al. American College of Rheumatology. Preliminary definition of improvement in rheumatoid arthritis. Arthritis Rheum 1995;38:727-35.
55. Felson DT, Anderson JK, Lange ML, Wells C, LaValley MP. Should improvement in rheumatoid arthritis clinical trials be defined as fifty percent or seventy percent improvements in core set measures, rather than twenty percent? Arthritis Rheum 1998;41:1564-70.
56. Feldmann M. What is the mechanism of action of anti-tumour necrosis factor-alpha antibody in rheumatoid arthritis? Int Arch Allergy Immunol 1996;111:362-5.
57. Feldmann M, Brennan FM, Maini RN. Rheumatoid arthritis. Cell 1996;85:307-10.
58. Maini RN, Elliott M, Brennan FM, Williams RO, Feldmann M. TNF blockade in rheumatoid arthritis: implications for therapy and pathogenesis. APMIS 1997;105:257-63.
59. Feldmann M, Brennan FM, Maini RN. Role of cytokines in rheumatoid arthritis. Annu Rev Immunol 1996;14:397-440.
60. Choy EHS, Panayi GS. Engineered human anti-tumor necrosis factor-alpha (TNFα) antibody, CDP571, in rheumatoid arthritis. In: Strand V, Scott DL, Simons LS, eds. Novel therapeutic agents for the treatment of autoimmune diseases. New York, NY: Marcel Dekker, 1997:121-9.
61. Sander O, Rau R. Clinical trials on biologies in rheumatoid arthritis. Int J Clin Pharmacol Ther 1998;36:621-4.
62. Moreland LW, Baumgartner SW, Schiff MH, et al. Treatment of rheumatoid arthritis with a recombinant human tumor necrosis factor receptor (p75)-Fc fusion protein. N Engl J Med 1997;337:141-7.
63. Moreland LW, Schiff MH, Baumgartner SW, et al. Etanercept therapy in rheumatoid arthritis: A randomized, controlled trial. Ann Intern Med 1999;130:478-86.
64. Feldmann M, Elliott MJ, Woody JN, Maini RN. Anti-tumor necrosis factor-alpha therapy of rheumatoid arthritis. Adv Immunol 1996;64:283-350.
65. Moreland LW, McCabe D, Caldwell JR, et al. Recombinant methionyl human tumor necrosis factor binding protein PEGylated dimer (TNFbp Dimer) in patients with active refractory rheumatoid arthritis. J Rheumatol (in press).
66. Edwards III CK, Frazier J, Seely J, et al. Assessment of the major antigenic epitopes of the recombinant human soluble p55 TNF type I receptor: design of a novel mono-meric non-immunogenic analog, sTNF-RI. Arthritis Rheum 1998;41:S58..
67. Parmely MJ, Zhou WW, Edwards III CK, Borcherding DR, Silverstein R, Morrison DC. Adenosine and a related carbocyclic nucleoside analogue selectively inhibit tumor necrosis factor-alpha production and protect mice against endotoxin challenge. J Immunol 1993;151:389-96.
68. Burger D, Chicheportiche R, Giri JG, Dayer J. The inhibitory activity of human interleukin-1 receptor antagonist is enhanced by type II interleukin-1 soluble receptor and hindered by type I interleukin-1 soluble receptor. J Clin Invest 1995;96:38-41.
69. Esser RE, Stimpson SA, Cromartie WJ, Schwab JH. Reactivation of streptococcal cell wall-induced arthritis by homologous cell wall polymers. Arthritis Rheum 1985;28: 1402-11.
70. Evans RJ, Bendele AM, Kieft GI, McAbee TJ, Edwards III CK. Efficacy of tumor necrosis factor binding protein (TNF-bp) in the streptococcal cell wall-induced reactivation model of arthritis. Arthritis Rheum 1996;39:S284.
71. Bendele A, McAbee T, Sennello G, Frazier J, Chlipala E, McCabe D. Efficacy of sustained blood levels of interleukin-1 receptor antagonist in animal models of arthritis. Arthritis Rheum 1999;42:498-506.
72. Martin S, Frazier J, Seely J, et al. A genetically modified tumor necrosis factor receptor I (sTNF-RI) that does not elicit antibody response in primates. Arthritis Rheum 1998;41:S58.
73. Martin SW, Sommers JS, Macri MJ, et al. The Pharmacokinetics of subcutaneous injections of PEGylated recombinant methiopnyl human soluble tumor necrosis factor-type I receptor (PEG sTNF-RI) in subjects with active rheumatoid arthritis. Arthritis Rheum (in press).
74. Caldwell JR, Davis MW, Jelaca-Maxwell K, et al. A phase 1 study of PEGylated soluble tumor necrosis factor receptor type I (PEG sTNF-RI [p55]) in subjects with rheumatoid arthritis (RA). Arthritis Rheum (in press).